OmniAb to Report Third Quarter 2026 Financial Results on October 30

Wed, 14 Oct 2026 16:05:00 -0400

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and nine months ended September 30, 2026, before the open of the U.S. financial markets on Friday, October 30, 2026, and will hold a conference call that same day beginning at 8:00 a.m. Eastern time.

Conference Call and Webcast

What:

OmniAb conference call to discuss third quarter 2026 financial results

OmniAb to Report Third Quarter 2026 Financial Results on October 30

Wed, 14 Oct 2026 16:05:00 -0400

Conference Call and Webcast

What:

OmniAb conference call to discuss third quarter 2026 financial results

OmniAb (OABI) Reiterated at Buy by Stifel on IMVT-1402 Data Disclosures

Wed, 07 Oct 2026 09:07:25 -0400

(Updated - October 7, 2026 9:07 AM EDT)

Stifel analyst Stephen Willey reiterated a Buy rating and $9.00 price target on OmniAb, Inc. (NASDAQ: OABI).

The analyst commented, "We’re reiterating our Buy-rated thesis following management’s investor event which provided 1) an updated overview of the base business and those partnered/clinical-stage assets anticipated to deliver meaningful near-term data catalysts and potentially provide the foundation for future royalty cash flow generation; 2) insight into the company’s licensing strategies and continued technological advancements achieved with the company’s avian-based transgenic model systems; 3) the reveal of a new peptide discovery technology (OmniTides) intended to provide a

OmniAb, Inc. (OABI) PT Raised to $6 at StoneX Following Analyst Day

Wed, 07 Oct 2026 08:55:31 -0400

(Updated - October 7, 2026 8:55 AM EDT)

StoneX analyst Robert Wasserman raised the price target on OmniAb, Inc. (NASDAQ: OABI) to $6.00 (from $4.00) while maintaining a Buy rating.

The analyst commented, "OmniAb held its first Investor and Analyst Day at its Emeryville, CA, headquarters on October 6. The company reiterated financial guidance for 2026E recently given in mid-August following the announcement of a collaboration agreement with Eli Lilly. Other highlights of the meeting included the launch of a new product line, OmniTides, targeted at the peptide development market, and the expansion of its xPloration Platform availability to all customers, beyond

OmniAb, Inc. (OABI) PT Raised to $6 at StoneX Following Analyst Day

Wed, 07 Oct 2026 08:55:31 -0400

(Updated - October 7, 2026 8:55 AM EDT)

StoneX analyst Robert Wasserman raised the price target on OmniAb, Inc. (NASDAQ: OABI) to $6.00 (from $4.00) while maintaining a Buy rating.

OmniAb expands xPloration platform access and launches peptide discovery unit

Tue, 06 Oct 2026 08:05:20 -0400

OmniAb, Inc. (NASDAQ: OABI) held an Investor & Analyst Day on October 6, 2026, in Emeryville, California, where the company outlined revenue expectations for its xPloration platform and introduced a new peptide discovery offering called OmniTides.

Beginning in October 2026, the xPloration platform became available for purchase by all customers, expanding commercial access beyond a Partner Access Program launched in 2025. OmniAb described the addressable market for xPloration as exceeding $500 million. The company projected xPloration revenue of between $2 million and $3 million in 2026, with expectations that revenue will double in 2027 and double again in 2028.

xPloration is an

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

Tue, 06 Oct 2026 08:00:00 -0400

Formal presentation begins today, October 6, 2026, at 11 a.m. ET

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today hosts its Investor & Analyst Day in Emeryville, CA. With a full presentation agenda, the event highlights recent partner developments, the broader roll out of the xPloration® platform, and introduces the OmniTides™ peptide discovery platform and brand.

“We look forward to bringing together our investment community and sharing a closer look at our technologies and capabilities, our strategy and the exciting opportunities ahead,” said Matt

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

Tue, 06 Oct 2026 08:00:00 -0400

Formal presentation begins today, October 6, 2026, at 11 a.m. ET

“We look forward to bringing together our investment community and sharing a closer look at our technologies and capabilities, our strategy and the exciting opportunities ahead,” said Matt

OmniAb to Host Investor & Analyst Day on October 6, 2026

Mon, 14 Sep 2026 08:00:00 -0400

The event will feature presentations from OmniAb’s executive leadership team, including corporate updates, select partner programs, the xPloration® platform, technology innovations and a Q&A session. For those attending in person, there will be demonstrations of the Company’s xPloration technology platform and laboratory tours.

OmniAb Investor & Analyst Day
Date: October 6, 2026
Time: 8 a.m. PT / 11

OmniAb to Host Investor & Analyst Day on October 6, 2026

Mon, 14 Sep 2026 08:00:00 -0400

OmniAb Investor & Analyst Day
Date: October 6, 2026
Time: 8 a.m. PT / 11

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

The Nasdaq/LD Micro Summit will take place at the Nasdaq Headquarters in San Francisco, CA. The H.C. Wainwright 28th Annual Global Investment Conference will take place at the Lotte New York Palace Hotel in New York City. Management will provide a brief corporate overview and be available for

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

OmniAb to Participate in Upcoming Investor Conferences

Wed, 26 Aug 2026 08:00:00 -0400

Nasdaq/LD Micro Summit Series
Date: Wednesday, September 9, 2026

H.C. Wainwright 28th Annual Global Investment Conference
Date: Tuesday, September 15, 2026

OmniAb raises 2026 cash guidance on licensing activity

Mon, 17 Aug 2026 06:06:47 -0400

OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, citing recent technology licensing activity, according to a company press release.

The Emeryville, Calif.-based antibody discovery technology licensor now expects to end 2026 with cash and cash equivalents in the range of $49 million to $53 million, up from its prior guidance of $37 million to $41 million.

Chief Executive Officer Matt Foehr attributed the revision to business development and licensing activity. "Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook," he said.

OmniAb licenses discovery research technology to pharmaceutical

OmniAb raises 2026 cash guidance on licensing activity

Mon, 17 Aug 2026 06:06:47 -0400

OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, citing recent technology licensing activity, according to a company press release.

OmniAb licenses discovery research technology to pharmaceutical

OmniAb raises 2026 cash guidance on licensing activity

Mon, 17 Aug 2026 06:06:47 -0400

OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, citing recent technology licensing activity, according to a company press release.

OmniAb licenses discovery research technology to pharmaceutical

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

“Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlook,” stated Matt Foehr, Chief Executive Officer of OmniAb. “Our business at OmniAb continues to strengthen as the reach of our novel technologies expands and as our partnerships become deeper

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

OmniAb Raises 2026 Financial Guidance

Mon, 17 Aug 2026 06:06:00 -0400

Increases Full Year 2026 Cash Outlook Following Recent Technology Licensing Activity

OmniAb and Eli Lilly reach ion channel drug discovery deal

Mon, 17 Aug 2026 06:01:20 -0400

OmniAb, Inc. (NASDAQ: OABI) announced a global collaboration and license agreement with Eli Lilly and Company for an ion channel drug discovery program, according to a press release from the Emeryville, California-based company.

Under the terms of the agreement, OmniAb will receive an upfront payment and is eligible to receive up to $370 million in research, development, and commercial milestone payments, along with tiered royalties on global net sales. The therapeutic target and modality were not disclosed.

The collaboration will use OmniAb's technology platform and its ion channel discovery and screening capabilities.

"We are pleased to enter into this important new relationship with

OmniAb and Eli Lilly reach ion channel drug discovery deal

Mon, 17 Aug 2026 06:01:20 -0400

The collaboration will use OmniAb's technology platform and its ion channel discovery and screening capabilities.

"We are pleased to enter into this important new relationship with

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Mon, 17 Aug 2026 06:01:00 -0400

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expertise in ion channel discovery and screening.

“We are pleased to enter into this important new relationship with Lilly,” said Matt Foehr, OmniAb’s Chief Executive Officer. “Lilly is focused on delivering medicines to address major unmet medical needs and our differentiated expertise and established technologies that relate to ion channels

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

Mon, 17 Aug 2026 06:01:00 -0400

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expertise in ion channel discovery and screening.

StreetInsider.com News Articles

OmniAb to Report Third Quarter 2026 Financial Results on October 30

OmniAb to Report Third Quarter 2026 Financial Results on October 30

OmniAb (OABI) Reiterated at Buy by Stifel on IMVT-1402 Data Disclosures

OmniAb, Inc. (OABI) PT Raised to $6 at StoneX Following Analyst Day

OmniAb, Inc. (OABI) PT Raised to $6 at StoneX Following Analyst Day

OmniAb expands xPloration platform access and launches peptide discovery unit

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day

OmniAb to Host Investor & Analyst Day on October 6, 2026

OmniAb to Host Investor & Analyst Day on October 6, 2026

OmniAb to Participate in Upcoming Investor Conferences

OmniAb to Participate in Upcoming Investor Conferences

OmniAb to Participate in Upcoming Investor Conferences

OmniAb to Participate in Upcoming Investor Conferences

OmniAb raises 2026 cash guidance on licensing activity

OmniAb raises 2026 cash guidance on licensing activity

OmniAb raises 2026 cash guidance on licensing activity

OmniAb Raises 2026 Financial Guidance

OmniAb Raises 2026 Financial Guidance

OmniAb Raises 2026 Financial Guidance

OmniAb Raises 2026 Financial Guidance

OmniAb and Eli Lilly reach ion channel drug discovery deal

OmniAb and Eli Lilly reach ion channel drug discovery deal

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company

OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company